Talc body powder claims: what to check

What is happening in the case right now, and what does that mean for someone new?

J&J announced a proposed deal for ovarian claims in July 2026. The company listed conditions that must be met. Ask a lawyer to check the actual proposal and latest court orders for your diagnosis. [3]

In its July 27, 2026 SEC exhibit, J&J said the proposal needs participation representing at least 95% of remaining claims. The exhibit is the company’s announcement, not a court award or proof that funds reached a person. It discusses mesothelioma separately. Ask which claim and agreement, if any, concern you. [3]

The New Jersey court’s January 20, 2026 report reviews whether expert evidence may be heard. Its author, retired Judge Freda L. Wolfson, served as a special master: a person appointed to help the court with specific tasks. This is a recommendation about evidence, not a decision that your illness was caused by powder. On July 22, 2026, the court granted a request to make plaintiffs explain why their claims should not be dismissed for lack of proof about what caused their own cancers. That step gave both sides a chance to be heard; it did not dismiss every claim. [1]

That report recounts the court’s rejection of Red River Talc’s bankruptcy plan in March 2025. It says the case was dismissed and the pause in the federal talc cases later ended. A failed company plan does not itself pay an injured person. The court’s public page names Michael A. Shipp among the judges overseeing the federal group. [1] [2]

What does it cost to get help?

Get the proposed fee and case-cost terms before hiring a lawyer for a powder claim. Ask what you could owe if it fails. Request plain written answers about expense deductions and the share of any money recovered. [12]

The ABA’s model fee rule calls for signed written terms when payment depends on the result. Those terms cover the lawyer’s share and whether expenses come out before or after that share. They also identify expenses owed without a win. A model rule does not certify a particular firm’s prices or every state’s rules. [12]

A talc review may raise questions about medical files, product tests or outside experts. Ask who orders any report and who pays for it. Do not buy a test just because a page mentions contamination. Ask whether an existing pathology report or product record should be reviewed first.

For patient access to records from a covered provider, HHS describes reasonable copying and mailing charges. The guidance does not allow a search or retrieval fee for that access. Ask the provider which request, permission and charges apply. The rules for sending records to a third party require separate care. [13]

What should I do today?

Talk with your doctor about symptoms and possible asbestos exposure, while keeping legal questions separate. NCI advises sharing the exposure history with a doctor. Make a short list of product use and the diagnosis for a lawyer to review. [11]

Gather the diagnosis report, care summaries and existing photos or product labels. Write approximate years of use if exact dates are unclear. Note powder used on the body and possible exposure from work or the home separately. Do not change an original record or guess a product’s ingredients from its brand name.

FDA’s 2019 notice told holders of Johnson’s Baby Powder lot 22318RB to stop using that recalled lot. The positive sample came from that lot; a sample from another lot tested negative. If you have an old bottle, check its exact label against the actual alert. That notice is not a finding about every bottle or your own diagnosis. [9]

Keep medical files out of public posts when seeking help. Ask who will receive them, what permission is requested and how contact details may be shared. HHS describes access rights for patients and proper representatives, with limits. This page does not certify the privacy terms of an intake service. [13] [14]

What is the evidence that the product causes this?

Studies and agency reviews raise concerns about talc and ovarian cancer, with important limits. They do not decide the cause of one person’s cancer. Asbestos-related disease also needs a separate review of the actual exposure and diagnosis. [4] [5] [6] [11]

A 2020 study pooled data from four groups of women followed over time. Its main analysis included 252,745 women. It found no clear statistical link overall between reported genital powder use and ovarian cancer. The authors said the study might miss a small rise in risk; they could not examine the specific type of powder. [4]

A 2024 Sister Study analysis updated reports of intimate-product use. It found a positive link with ovarian cancer across the corrections it examined for errors in remembered use. The results depend on those assumptions and missing data. Some women in this study also contributed to the earlier pooled analysis, so these are not fully separate groups. [5] [4]

IARC’s July 2024 review classified talc as probably able to cause cancer. It combined limited human evidence with animal and cell evidence. Reporting errors and possible asbestos contamination complicated the human findings. The authors of the 2024 study also said their results do not pinpoint a cause or mechanism. [6] [5]

IARC identifies cancer hazards, not a person’s risk from a specific dose. Its talc review treated asbestos-containing talc separately. FDA found no asbestos in its 50 selected samples from 2023, while its 2019 alert concerned a positive sample from one lot. These records do not prove that all powders are contaminated or that all are safe. [6] [8] [9]

Ask your doctor to explain the diagnosis and your lawyer to explain the proof needed for your claim. A group-level association, a product test and a court’s evidence rule answer different questions. Keep the study limits beside the findings when you read an advertisement. Do not turn either a positive association or a negative sample into a conclusion about your own illness. [4] [5] [8] [1]

Sources

These sources include two original studies, cancer-agency guidance and dated public records. The company exhibit is a proposal announcement; the court report is a recommendation about expert evidence. Each supports only its stated scope, and citing an author or judge does not mean that person reviewed this page. [4] [5] [3] [1]

Ovarian Cancer (Talc-Related) and Mesothelioma

Talcum powder litigation encompasses two primary cancer diagnoses. Ovarian cancer is a malignant neoplasm originating in the ovarian epithelium, with talc-related cases arising from chronic inflammatory stimulation caused by talc particles that migrate from the perineal area to the ovarian surface. Mesothelioma is a rare and aggressive cancer of the mesothelial lining caused by asbestos fibers present as contaminants in talc products. Both conditions are life-threatening, with ovarian cancer having a 5-year survival rate of approximately 50% overall and mesothelioma having a median survival of 12 to 21 months after diagnosis.

Abdominal bloating and pelvic pain (ovarian cancer)

Persistent abdominal bloating, pelvic pain or pressure, and a feeling of fullness are among the earliest symptoms of ovarian cancer. These symptoms are often vague and may be attributed to gastrointestinal or menstrual issues, contributing to late-stage diagnosis in many cases.

Changes in bowel or bladder habits (ovarian cancer)

Increased urinary frequency, urgency, constipation, or changes in bowel habits that persist for more than a few weeks may indicate ovarian cancer, particularly when combined with other symptoms.

Unexplained weight loss or loss of appetite (ovarian cancer)

Unintentional weight loss and persistent loss of appetite or early satiety (feeling full quickly) can indicate advanced ovarian cancer, often associated with ascites (fluid accumulation in the abdomen).

Shortness of breath and chest pain (mesothelioma)

Pleural mesothelioma (lining of the lungs) commonly presents with progressive shortness of breath, chest pain, and persistent cough. Pleural effusion (fluid between the lung and chest wall) is frequently present at diagnosis.

Abdominal pain and swelling (peritoneal mesothelioma)

Peritoneal mesothelioma (lining of the abdomen) presents with abdominal pain, distension, ascites, nausea, and bowel obstruction. It is associated with ingested or migrated asbestos fibers from contaminated talc products.

Fatigue and general malaise

Profound fatigue that does not improve with rest is common in both ovarian cancer and mesothelioma, often reflecting the body’s inflammatory response to the cancer and the metabolic demands of tumor growth.

• Long-term perineal use of talcum powder (strongest risk factor for ovarian cancer — daily use over 10+ years confers highest risk)
• Exposure to asbestos-contaminated talc products (risk factor for mesothelioma regardless of application site)
• Family history of ovarian cancer or BRCA1/BRCA2 gene mutations (increases baseline ovarian cancer risk independent of talc)
• Occupational talc or asbestos exposure (mining, milling, cosmetic manufacturing)
• History of endometriosis, which independently increases ovarian cancer risk and may interact with talc exposure
• Nulliparity (never having given birth) and late menopause, which increase cumulative ovulatory cycles and baseline ovarian cancer risk
• Pelvic examination and imaging: Transvaginal ultrasound and CT/MRI scans of the pelvis and abdomen to identify ovarian masses or suspicious findings
• CA-125 blood test: Measures levels of cancer antigen 125, a biomarker often elevated in ovarian cancer (though not specific to ovarian cancer)
• Biopsy and pathological examination: Surgical removal or biopsy of suspicious tissue for microscopic examination to confirm cancer type and grade
• Staging: Comprehensive surgical staging for ovarian cancer (FIGO staging system) or imaging-based staging for mesothelioma to determine disease extent
• Pathology review for talc particles: In litigation-relevant cases, pathology examination of tumor tissue may identify talc particles embedded in or adjacent to the tumor, providing direct evidence of talc exposure
• Asbestos fiber analysis: For mesothelioma cases, analysis of tumor tissue for asbestos fiber type and concentration to confirm the asbestos exposure pathway
• Cytoreductive surgery (debulking): Surgical removal of as much tumor as possible, often including removal of ovaries, fallopian tubes, uterus, omentum, and visible tumor deposits. Optimal debulking is the single most important prognostic factor in ovarian cancer.
• Platinum-based chemotherapy: Standard first-line chemotherapy for ovarian cancer combines carboplatin with paclitaxel. Six cycles administered intravenously over 18 weeks. Response rates are high but recurrence is common in advanced disease.
• PARP inhibitors: Targeted therapy drugs (olaparib, niraparib, rucaparib) that block DNA repair in cancer cells, particularly effective in patients with BRCA mutations or homologous recombination deficiency.
• Immunotherapy: Pembrolizumab (Keytruda) and bevacizumab (Avastin) are used in combination with chemotherapy for advanced ovarian cancer. Immunotherapy is also being studied in mesothelioma treatment.
• Multimodal mesothelioma treatment: Combination of surgery (pleurectomy/decortication or extrapleural pneumonectomy), chemotherapy (pemetrexed + cisplatin), and radiation therapy. Treatment is palliative in most cases due to the disease’s aggressiveness.
• Clinical trials: Ongoing clinical trials for both ovarian cancer and mesothelioma offer access to novel therapies including new targeted agents, immunotherapy combinations, and gene therapy approaches.

The prognosis for talc-related cancers varies significantly by cancer type and stage at diagnosis. Ovarian cancer detected at stage I has excellent survival rates (90-95% at five years), but the majority of cases are diagnosed at stage III or IV because early symptoms are vague and easily overlooked, resulting in an overall 5-year survival rate of approximately 50%. Mesothelioma carries a particularly grim prognosis, with median survival of 12 to 21 months after diagnosis and a 5-year survival rate of 10-15%. The severity and lethality of these cancers — combined with the evidence that J&J knew its products contributed to their development — is what drives the substantial damage awards in the talcum powder litigation.

• https://www.cancer.org/cancer/ovarian-cancer.html — American Cancer Society: Ovarian Cancer Information
• https://www.cancer.gov/types/ovarian — National Cancer Institute: Ovarian Cancer
• https://www.mesothelioma.com — Mesothelioma Information and Support Resources
• https://ocrahope.org — Ovarian Cancer Research Alliance (OCRA)

How Litigation Is Impacting Johnson & Johnson

The talcum powder litigation has imposed catastrophic financial, reputational, and operational costs on Johnson & Johnson — one of the world’s largest consumer health companies. Billions of dollars in verdicts, the failure of J&J’s bankruptcy strategy, the discontinuation of its iconic Baby Powder product, and ongoing MDL proceedings have fundamentally altered the company’s risk profile and public image.

Product Withdrawal and Regulatory Pressure

J&J has faced product discontinuation, regulatory enforcement, congressional scrutiny, and the collapse of its bankruptcy strategy in response to mounting evidence that its talcum powder products caused cancer.

• J&J voluntarily recalled 33,000 bottles of Baby Powder after FDA found asbestos contamination (October 2019)
• J&J discontinued talc-based Baby Powder in North America (May 2020) and globally (August 2022)
• Third Circuit rejected J&J’s LTL Management bankruptcy strategy twice (2023, 2025), finding it was not filed in good faith
• Imerys Talc America — J&J’s primary talc supplier — filed Chapter 11 bankruptcy in February 2019; as of March 2026, the bankruptcy court had not ruled on confirmation of its plan
• Congressional hearings examined FDA oversight of cosmetic talc safety and J&J’s role in influencing testing standards
• Multiple countries including Sri Lanka and Indian states considered or implemented restrictions on talc-based cosmetic products

The talcum powder litigation has cost J&J billions of dollars in verdicts and settlements, forced the discontinuation of its flagship Baby Powder product, and resulted in the embarrassing public rejection of its bankruptcy strategy by federal appellate courts. With 69,340 actions pending in MDL 2738 on October 1, 2026, and a July 2026 J&J proposal for ovarian claims that depends on at least 95% participation, J&J’s talc liability remains one of the largest contingent liabilities in corporate America. The litigation trajectory mirrors tobacco and opioid litigation in its scale and its potential to fundamentally reshape industry practices.

Talcum Powder Lawsuit Filing Deadlines

Every state has a statute of limitations — a legal deadline — for filing a talcum powder lawsuit. Whether that time has passed depends on your facts, so don't rule yourself out. A lawyer can tell you. Because talc-related cancers can develop decades after exposure began, most states apply a "discovery rule" that affects when the clock starts.

The Discovery Rule: When Does the Clock Start?

Talc-related cancers have latency periods that can span decades. A woman who used Baby Powder daily in the 1980s may not be diagnosed with ovarian cancer until the 2020s. The discovery rule recognizes this reality by starting the statute of limitations when you discovered — or reasonably should have discovered — that your cancer was caused by or linked to talcum powder use. For many plaintiffs, this date is the date of cancer diagnosis, the date a physician linked their cancer to talc exposure, or the date they learned of the connection through media coverage or legal advertising. The discovery rule is critical in talcum powder cases because it prevents the statute of limitations from expiring before a plaintiff even knows they have a claim.

A woman diagnosed with ovarian cancer in 2024 who used Baby Powder for perineal hygiene for 25 years

In most states, the statute of limitations starts in 2024 when the cancer was diagnosed — not when she first began using Baby Powder in the 1990s. The diagnosis date is typically the earliest point at which the connection between talc use and cancer could reasonably be discovered.

A man diagnosed with mesothelioma in 2023 who worked in a talc mining operation in the 1980s

Mesothelioma has a latency period of 20 to 50 years. The discovery rule starts the clock at diagnosis in 2023, giving the plaintiff the full statute of limitations period from that point. Without the discovery rule, the claim would be time-barred before the disease even manifested.

A family learns in 2025 that their mother’s 2020 ovarian cancer death may have been caused by decades of Baby Powder use after seeing media coverage of the Craft verdict

For wrongful death claims, the discovery rule may start when surviving family members learned or should have learned of the connection between talcum powder and their loved one’s cancer. Media coverage, legal advertising, or a physician’s opinion linking the cancer to talc use may trigger the discovery date.

MDL 2738 in the District of New Jersey listed 69,340 pending actions on October 1, 2026. On July 27, 2026, J&J announced a proposed resolution of ovarian claims that depends on participation representing at least 95% of remaining claims; it does not say what any one person would receive. Whether your filing deadline has passed depends on your facts, so don't rule yourself out. A lawyer can tell you.

This table provides general guidance. Actual deadlines depend on your specific circumstances, including when you were diagnosed, when you discovered the connection between talc use and your cancer, and the applicable state law. An attorney can determine your exact deadline based on the facts of your case.